About talazoparib
PARP inhibitor anticancer medicine
Used for
- Treats certain inherited BRCA-mutated breast cancers
- Treats some advanced prostate cancers with specific gene changes
Usual adult dose
Usually 1 mg by mouth once daily for breast cancer; prostate cancer treatment may combine it with enzalutamide. Dose adjustments may be needed.
Common side effects
- Low blood-cell counts, including anemia and low platelets
- Tiredness or weakness
- Nausea, vomiting, or diarrhea
- Hair loss or reduced appetite
Important warnings
- Can cause serious anemia, infection risk, or bleeding from low blood counts
- Rarely causes myelodysplastic syndrome or acute leukemia
- May harm an unborn baby; effective contraception is needed
- Swallow capsules whole; do not open or dissolve them
Pregnancy
May cause fetal harm. Avoid during pregnancy; use effective contraception during treatment and for at least 7 months afterward.
Breastfeeding
Do not breastfeed during treatment and for at least 1 month after the final dose.
Interactions
- P-glycoprotein inhibitors, such as itraconazole, may increase talazoparib exposure
- P-glycoprotein inducers, such as rifampin, may lower exposure
- Other medicines that suppress bone marrow may worsen low blood counts
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.